Xenikos Set To Start Phase III For Acute GVHD Drug

 
• By Kevin Grogan

The Dutch biotech's CEO tells Scrip that one-week treatment with T-Guard could change the paradigm for tackling steroid-refractory graft-versus-host disease.

Doors
Xenikos ready to enter Phase III • Source: Shutterstock

More from Clinical Trials

More from R&D